First Oral Cholesterol Pill, Five-State Parasite Outbreak, and Africa's Converging Fevers

This weekend in health: the cardiovascular milestone of an oral cholesterol pill, a restaurant-lettuce recall affecting five US states, and two distinct haemorrhagic fever viruses circulating simultaneously in East Africa.

Thursday, 16 July: Merck's Lipfendra Becomes the World's First Oral PCSK9 Inhibitor for High Cholesterol

The US Food and Drug Administration approved Lipfendra (enlicitide decanoate) this week, making it the first oral drug ever cleared to block the PCSK9 protein and lower LDL-cholesterol — adding a once-daily pill to an arena previously served only by injectable biologics.

PCSK9 inhibitors work by preserving LDL receptors on the surface of liver cells. Under normal physiology, the PCSK9 enzyme marks those receptors for degradation, reducing the liver's capacity to remove LDL — often called "bad cholesterol" — from the bloodstream. When PCSK9 is blocked, receptors remain active longer and clear more LDL. The two existing injectable agents, evolocumab (Repatha, Amgen) and alirocumab (Praluent, Sanofi), reduce LDL-C by 50–60 percent but require subcutaneous injections every two to four weeks — a practical and adherence barrier for a meaningful proportion of patients.

Merck's enlicitide is a macrocyclic peptide taken by mouth once daily. Its approval rested on two Phase 3 pivotal trials in the CORALreef programme: CORALreef Lipids (broad hypercholesterolaemia) and CORALreef HeFH, which enrolled patients with heterozygous familial hypercholesterolaemia, a genetic condition causing dangerously elevated LDL from birth. At 24 weeks, LDL-C was reduced by 56 percent and 59 percent compared with placebo in those two trials, respectively — a magnitude comparable to the injectable PCSK9 class.

An important caveat: Lipfendra does not yet have long-term cardiovascular outcomes data. The injectable agents have demonstrated direct reductions in heart attacks and strokes in large outcomes trials; that evidence does not yet exist for enlicitide. Merck has committed to conducting outcomes trials, and the FDA label acknowledges the gap explicitly. Clinicians should explain to patients that LDL reduction, while a robust and well-validated surrogate for cardiovascular risk, is not the same as proven event prevention. Pricing and insurance access — prior authorisation requirements have constrained uptake of injectable PCSK9 inhibitors despite strong evidence — will also shape how broadly this pill reaches patients who need it.

Friday, 17 July: CDC Confirms Cyclospora Outbreak Tied to Taco Bell Iceberg Lettuce; 1,644 Sickened in Five States

US public health authorities confirmed on Friday that shredded iceberg lettuce served at Taco Bell restaurants in Indiana, Kentucky, Michigan, Ohio, and West Virginia is the source of a multistate Cyclospora cayetanensis outbreak that has sickened at least 1,644 people and hospitalised 94 since mid-May 2026.

Cyclospora is a single-celled intestinal parasite — not a bacterium — that causes a distinctive and often prolonged illness: profuse watery diarrhoea, fatigue, and loss of appetite that may initially improve and then relapse over weeks if untreated. The parasite spreads when produce or water is contaminated with Cyclospora oocysts from human faecal matter. A critical point for health care providers: the broad-spectrum antibiotics commonly prescribed for food-borne bacterial infections do not treat Cyclospora. Confirmed or suspected cyclosporiasis requires a specific prescription, trimethoprim-sulfamethoxazole, and clinicians should consider that diagnosis when a patient's symptoms match the exposure window and geography.

FDA and CDC traceback investigations identified shredded iceberg lettuce supplied by Taylor Farms de México, sourced from farms in central Mexico, as the probable contaminated source. On Friday, Taylor Farms de México announced it would voluntarily withdraw all such lettuce from the US market. Taco Bell confirmed the product has been removed from affected restaurant locations. The CDC advises that anyone who ate shredded iceberg lettuce at a Taco Bell in the five named states between 13 May and 17 July 2026 and developed diarrhoea, fatigue, or loss of appetite lasting more than a few days should contact a health care provider and specify the potential Taco Bell exposure, as that information will guide appropriate testing and treatment.

Ongoing: Bundibugyo Ebola Outbreak in DRC and Uganda Surpasses 400 Deaths

The Ebola outbreak first reported in this roundup when confirmed cases passed 1,800 has now crossed 400 deaths, according to figures compiled by the Center for Infectious Disease Research and Policy this week. The responsible agent is Bundibugyo virus, one of six recognised species in the Ebolavirus genus. Bundibugyo typically carries a lower case fatality rate than the Zaire species responsible for the 2014–2016 West African epidemic, but it remains a lethal haemorrhagic fever without an approved therapeutic beyond supportive care.

The outbreak spans the Democratic Republic of Congo and affected zones of neighbouring Uganda. The CDC has published interim guidance for assessment and management of travellers returning from affected countries, including protocols for symptom monitoring and, in higher-risk exposures, active public health follow-up. Community engagement and access remain challenges; DRC has experienced multiple Ebola outbreaks in the past decade, building hard-won institutional knowledge while also generating, in some communities, fatigue with isolation and quarantine practices.

Ongoing: WHO Awaits Marburg Update from Uganda as a Second Haemorrhagic Fever Complicates East Africa Response

A significant complication has emerged in the same geographic corridor: Uganda confirmed in late June that a one-and-a-half-year-old child died of Marburg virus disease in Kyegegwa District in western Uganda — introducing a second distinct filoviral haemorrhagic fever into a region already managing an Ebola response.

Marburg virus belongs to the same filovirus family as Ebolavirus but is a different genus. The two diseases produce clinically similar syndromes — fever, severe myalgia, and in serious cases haemorrhage — but are genetically distinct, require different laboratory assays to differentiate, and no single intervention covers both. Health workers in the affected region must now test seriously ill patients for both pathogens simultaneously, maintain parallel supply chains for two sets of diagnostic reagents and personal protective equipment, and run concurrent contact-tracing operations for two biologically distinct viruses. This logistical challenge compounds an already strained regional health system response.

Uganda's Health Minister initially stated there was no evidence of active Marburg transmission beyond the index case, but as of 16 July the World Health Organization had made repeated requests for updated epidemiological information and was still awaiting a response from Ugandan health authorities. The Africa CDC has characterised the Uganda Marburg event as isolated. For the public: there is currently no indication of Marburg risk beyond Kyegegwa District — this is a contained event under investigation, not a spreading outbreak. Travellers to western Uganda should consult WHO advisories before and during any planned travel to the region.

The content in this article is journalistic reporting and does not constitute medical advice. Readers should consult a qualified clinician before making any changes to their treatment, medication, or health regimen.